Denali Therapeutics Inc. (DNLI): Price and Financial Metrics


Denali Therapeutics Inc. (DNLI)

Today's Latest Price: $22.33 USD

0.22 (1.00%)

Updated Jan 17 1:38pm

Add DNLI to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 213 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

DNLI Stock Summary

  • DNLI's went public 2.11 years ago, making it older than just 5.38% of listed US stocks we're tracking.
  • Of note is the ratio of Denali Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 9.99% of US stocks have a lower such ratio.
  • With a price/sales ratio of 14.79, Denali Therapeutics Inc has a higher such ratio than 92.19% of stocks in our set.
  • Stocks that are quantitatively similar to DNLI, based on their financial statements, market capitalization, and price volatility, are MOR, ARGX, ESPR, UTHR, and FATE.
  • Visit DNLI's SEC page to see the company's official filings. To visit the company's web site, go to www.denalitherapeutics.com.
DNLI Daily Price Range
DNLI 52-Week Price Range

DNLI Stock Price Chart More Charts


DNLI Price/Volume Stats

Current price $22.33 52-week high $28.86
Prev. close $22.11 52-week low $14.24
Day low $21.90 Volume 417,817
Day high $22.72 Avg. volume 637,396
50-day MA $17.91 Dividend yield N/A
200-day MA $19.27 Market Cap 2.14B

Denali Therapeutics Inc. (DNLI) Company Bio


Denali Therapeutics Inc. engages in discovering and developing therapeutics for neurodegenerative diseases in the United States. The company’s lead LRRK2 product candidates includes the DNL201, a small molecule inhibitor that is in Phase I clinical trials, as well as DNL151, a small molecule inhibitor, which is in preclinical development stage for the treatment of Parkinson’s disease. It is also developing therapeutics for the treatment of Parkinson’s, dementia with Lewy bodies, and multiple system atrophy; amyotrophic lateral sclerosis; and mucopolysaccharidosis type II patients. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was founded in 2013 and is based in South San Francisco, California.





DNLI Latest News Stream


Event/Time News Detail
Loading, please wait...

DNLI Latest Social Stream


Loading social stream, please wait...

View Full DNLI Social Stream

DNLI Price Returns

1-mo 20.77%
3-mo 55.07%
6-mo 7.25%
1-year 6.33%
3-year N/A
5-year N/A
YTD 28.19%
2019 -15.68%
2018 32.10%
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.497 seconds.